ARROWHEAD PHARMACEUTICALS ANNOUNCES HEALTH CANADA APPROVAL OF REDEMPLO™ (PLOZASIRAN) TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Reuters · 6d ago

Please log in to view news